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Background: BRAT1 (BRCA1-associated ATM activator 1) interacts with both BRCA1, ATM and DNA-PKcs, and has
been implicated in DNA damage responses. However, based on our previous results, it has been shown that BRAT1
may be involved in cell growth and apoptosis, besides DNA damage responses, implying that there are undiscovered
functions for BRAT1.
Methods: Using RNA interference against human BRAT1, we generated stable BRAT1 knockdown cancer cell lines of
U2OS, Hela, and MDA-MA-231. We tested cell growth properties and in vitro/in vivo tumorigenic potentials of BRAT1
knockdown cells compared to control cells. To test if loss of BRAT1 induces metabolic abnormalities, we examined the
rate of glycolysis, ATP production, and PDH activity in both BRAT1 knockdown and control cells. The role of BRAT1 in
growth signaling was determined by the activation of Akt/Erk, and SC79, Akt activator was used for validation.
Results: By taking advantage of BRAT1 knockdown cancer cell lines, we found that loss of BRAT1 expression
significantly decreases cell proliferation and tumorigenecity both in vitro and in vivo. Cell migration was also
remarkably lowered when BRAT1 was depleted. Interestingly, glucose uptake and production of mitochondrial ROS
(reactive oxygen species) are highly increased in BRAT1 knockdown HeLa cells. Furthermore, both basal and induced
activity of Akt and Erk kinases were suppressed in these cells, implicating abnormality in signaling cascades for cellular
growth. Consequently, treatment of BRAT1 knockdown cells with Akt activator can improve their proliferation and
reduces mitochondrial ROS concentration.
Conclusions: These findings suggest novel roles of BRAT1 in cell proliferation and mitochondrial functions.
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BRAT1 (BRCA1-associated ATM activator-1) was iso-
lated as BRCA1 binding protein, interacting with the
BRCT domain of BRCA1 [1]. Biochemical analysis indi-
cated that pathogenic forms of the BRCT domain of
BRCA1 protein (e.g. M1775R) do not bind to BRAT1,
suggesting BRCA1/BRAT1 interaction is important for
BRCA1’s tumor-suppressive functions. Mechanisms of
sensing and repairing DNA lesions are well conserved
among the species, and ATM, ATR and DNA-PK are es-
sential for this mechanism [2]. Subsequent studies have
shown that BRAT1 also binds to ATM and DNA-PKs,
implicating the broad role of BRAT1 in DNA repair as
well as in DNA damage response in general [1,3,4].* Correspondence: Toru.Ouchi@RoswellPark.org
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unless otherwise stated.Previous studies have also illustrated BRAT1 acts as a
regulator of cell growth and apoptosis. When BRAT1
was knocked down in mouse embryonic fibroblasts
(MEFs) and human osteosarcoma cell (U2OS), a consti-
tutive level of apoptosis was increased [1]. Interestingly,
these studies have shown that ionizing radiation (IR)
does not further induce apoptosis of these BRAT1
knockdown cells.
Recent genetic mapping and exome sequencing ana-
lysis identified that insertion mutations in the BRAT1
coding exon are pathogenic and cause lethal neonatal ri-
gidity and multifocal seizure syndrome (RMFSL) [5,6].
This disease is a lethal, neonatal, neurologic disorder
characterized by episodic jerking, lack of psychomotor
development, axial and limb rigidity, frequent multifocal
seizures, and dysautonomia. Infants show poorly respon-
sive focal jerks of the tongue, face and arms in a nearlyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cate the clinical relevance of BRAT1 pathways.
Mitochondria are critical organelles with important
roles in cellular energy metabolism, which produces
ATP via tricarboxylic acid (TCA) cycle and oxidative
phosphorylation (OXPHOS) [7]. Also, mitochondria plays
a key role in program cell death (apoptosis) as major
site, where pro- and anti-apoptotic proteins interact and
activates, so-called, mitochondria-dependent intrinsic
apoptosis [8]. Mitochondrial failure by chemical or under
disease condition induces increased reactive oxygen spe-
cies (ROS) generation and mitochondrial membrane po-
tential loss, leading to sequential apoptotic pathways, such
as release of cytochrome c and activation of caspases [9].
Recent studies suggested that ROS generation and in-
hibition in mitochondrial functions are critical steps in
chemical or knockdown-induced apoptosis of cancer
cells [10-12]. In contrast, since Warburg discovered
metabolic alterations in cancer cells (Warburg effect,
the increase in aerobic glycolysis and the dependency
on glycolytic pathway for ATP generation) [13,14], a
mitochondrial malfunction in respiration systems, due
to mitochondrial DNA mutations/deletions, has been
known as one of typical phenotypes in tumor tissues
and cells [15,16].
Recently, our previous studies showed the potential
roles of BRAT1 not only in DNA damage responses, but
also cell growth and apoptosis [1,17]. In current study,
we found that BRAT1 is involved in cellular growth
properties including cell proliferation and tumor growth,
and required for mitochondrial homeostasis, describing
new roles of BRAT1 in cell growth and metabolism, and
providing novel strategies for cancer treatment.Methods
Cells and reagents
HeLa (human cervical carcinoma), U2OS (osteosar-
coma), and MDA-MA-231 (human adenocarcinoma)
cells were purchased from American Type Culture Col-
lection (ATCC, Manassas, VA). All of these cells were
cultured in DMEM media (Invitrogen, Carlsbad, CA)
containing 10% fetal bovine serum (FBS, Invitrogen)
and antibiotics. For starvation experiments, FBS were
deprived for 24 h. Hydroxyurea (HU), Neocarzinostatin
(NCS), and 2-Dexyl-D-glucose (2DG) were purchased
from Sigma (St. Louis, MO). SC79, Akt activator was
provided by Dr. Hongbo R. Luo (Harvard Medical
School, Boston, MA). MitoTracker (mitochondrion-
selective probe), MitoSOX (mitochondrial superoxide
indicator), and CM-H2DCFDA (general oxidative stress
indicator) were obtained from Invitrogen. JC-1 (mito-
chondrial membrane potential dye) was purchased from
eBioscience (San Diego, CA).Plasmid and BRAT1 knockdown stable cell lines
Sure Silencing shRNA plasmids for human C7orf27 were
purchased from SABiosciences (Valencia, CA). To avoid
nonspecific targeting and increase efficiency, 4 independent
target sequences and 1 nonspecific sequences (NC) were
used as follows: #1: CCAGGACCCTGAGAGTTATGT, #2:
TCTCTTCCTGAGGGACAAGAT, #3: GAGTTACTACC
AGGGCTCTTT, #4: GCAGTTCCTCAGAGAGCTGTT,
and NC: GGAATCTCATTCGATGCATAC. U2OS, HeLa,
and MDA-MA-231 cells were transfected with shRNA
plasmids using Lipofectamine 2000 transfection reagent
(Invitrogen) according to manufacturer’s instruction. Cells
were then cultured for 2 weeks in 3 μg/ml puromycin (Cal-
biochem, Billerica, MA) and single cell colonies were
picked for analysis for BRAT1 expression by western blot.
Immunoblotting and protein assays
Cells were treated for the indicated time, and then lysed
in ice-cold lysis buffer (50 mM Tris–HCl (pH 7.6), 150
mM NaCl, 1 mM EDTA (pH 8.0), 20 mM NaF, 1 mM
Na3VO4, 1% NP40, 0.5 mM dithiothreitol) in the pres-
ence of protease-inhibitor mix (leupeptin, aprotinin,
and Phenylmethylsulfonyl fluoride, 10 μg/ml, respect-
ively). After centrifugation (12000 g, 10 min), soluble
supernatants were prepared and protein concentrations
were calculated using the Bio-Rad protein assay kit.
Total cell lysate (20 μg) was loaded and separated by
6.0% SDS polyacrylamide gels. Transfer to a PVDF
membrane (Immobilon-P, Millipore) was done using
semidry transfer method (Trans-Blot, Bio-Rad) in 25
mM Tris, 192 mM glycine, and 10% methanol for 1 h at
20 V. Membranes were blocked in 5% nonfat dried milk
in Tris-buffered saline (TBS)/0.1% Tween 20 and incubated
with primary antibodies and horseradish peroxidiseconju-
gated secondary antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA) followed by enhanced chemilumines-
cence detection. Primary antibodies used in this study
were anti-Akt, anti-Erk (Santa Cruz Biotechnology),
anti-BRAT1 (abcam, Cambridge, MA), anti-mTOR (Cell
Signalling Technology, Danvers, MA). Also specific anti-
phosphorylation antibodies were used against phospho
Akt (Ser473, Thr308), phosphor-mTOR (Ser2448) and
phosphor-Erk (Thr202/Tyr204) (Cell Signaling). Anti-
actin antibody (Santa Cruz Biotechnology) was used to
validate protein amount.
Cell cycling and apoptosis analysis using flow cytometer
Both control and BRAT1 knockdown cells were exposed
to vehicle (DMSO), or NCS (1 μg/ml) or HU (5 μM) for
24 h. Cell cycle arrest was assessed by ploidy analysis
after DNA staining with propidium iodide using flow
cytometer (FACSCalibur, BD Biosciences, Franklin Lakes,
NJ) as previously described [18]. Apoptosis was de-
termined by annexinV/PI double staining kits (BD
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For experiment involving glucose starvation, cells were
grown in DMEM with or without glucose for indicated
days, and stained with PI. 2DG-induced apoptosis was
determined compared with that in PBS-treated cells
after 24 h treatment. The data were analyzed with Cell-
QuestPro software (BD Biosciences).
Wound healing and migration assay
Cells were treated with mitomycin C (30 μg/ml) for 30
min before a wound was made. The injury lines were
created on 100% confluent monolayers of cells by scrap-
ing a gash using a micropipette tip. After being washing
with PBS, cells were cultured in 10% complete DMEM
for 46 h to be monitored wound healing. Photographs
were taken at 22 h and 46 h under 40× magnifications
using a SPOT Insight mosaic microscope camera (SPOT
Imaging Solutions, Sterling Heights, MI) attached to
Leica DM IRB microscope (Buffalo Grove, IL). For mi-
gration assay, control and BRAT1 knockdown MDA-
MA-231 cells were suspended with 0.3 ml plain DMEM
and then seed into 8.0 μm migration filters (BD FAL-
CON) placed in 24-well plates. Complete DMEM
medium 0.6 ml was added to the lower chamber. The
plates were then incubated at 37°C for 16 h. Cells on the
upper membrane surface were removed using a cotton
tip, and migrated cells (on lower membrane surface)
were fixed and stained by Diff-Quick stain kit (Siemens,
Malvern, PA). The migration rate was determined by
counting cells on lower side of membrane. Photographs
were taken under 10× magnifications using Olympus
DP70 digital camera (Center Valley, PA) attached to a
Leica MZ 12 s microscope.
Tumor formation in nude mice
Female athymic nude mice were purchased from Jackson
lab (Bar Harbor, Maine), and housed in specific
pathogen-free conditions. A total 2 × 106 control and
BRAT1 knockdown cells were subcutaneously injected
into the flanks of nude mice. Mice were checked daily to
examine tumor development, and tumor size was re-
corded at indicated days. Mice were euthanized and final
tumors were isolated from mice, and then photographs
were taken. These procedures were approved by the In-
stitutional Animal Care and Use Committee (IACUC) of
Roswell Park Cancer Institute.
Cell proliferation assays
For direct cell number detection, cell were detached at
indicated day by 0.1% Trypsin/EDTA solution (Invitro-
gen), and washed with PBS. Cell suspensions were mixed
with an equal volume of 0.4% trypan blue (VWR, Rad-
nor, PA), and viable cells (trypan blue negative cells)
were counted. In some experiments, cell proliferation/viability was measured by an MTT assay (BMR Service,
Buffalo, NY) according to manufacturer’s instruction. In
brief, cell medium was aspirated and then 0.3 ml MTT
working solution was added into 24 well. After 30 min
incubation at 37oC, MTT solution was aspirated, and
cells were incubated with 0.3 ml DMSO for 2 min. The
DMSO extracts were transferred to a 96-well plate and
absorbance was measured with micro-plate reader at a
wavelength of 540 nm.
ROS detection and measurement of mitochondrial
membrane potential
For measurement of mitochondrial ROS, cells were cul-
tured in complete DMEM containing 5 μM Mitosox for
10 min at 37°C, protected from light. Cells were washed
three times with warm PBS, and then mounted with
mounting medium with DAPI (Vector lab, Burlingame,
CA). Fluorescent images were captured using Nikon
TE2000-E inverted microscope equipped with a Roper
CoolSnap HQ CCD camera (Melville, NY, USA). For de-
tection of cellular ROS, cells were incubated with 5 μM
CM-H2DCFDA for 1 h at 37°C, and then subjected to
fluorescence microscopy. For quantitative assay, cells
were detached by 0.1 trypsin/EDTA solution after incu-
bation in Mitosox or CM-H2DCFDA working solution.
Cell suspensions were analyzed by flow cytometry. To
determine mitochondrial membrane potential, cells were
stained with JC-1(2.5 μg/ml) for 10 min at room
temperature and then analyzed by flow cytometry.
Determination of Pyruvate dehydrogenase (PDH) activity
and measurement of mitochondrial and intracellular ATP
PDH activity of control and BRAT1 knockdown cells
was analyzed by Pyruvate Dehydrogenase assay kit (BMR
Service). Membrane fraction was collected from cell ly-
sates and re-suspended for assay. PDH activity was mea-
sured as O.D at 492 nm using microplate reader. Protein
assay was performed to determine sample protein con-
centration before analysis. To measure of mitochondrial
ATP, mitochondria were isolated by mitochondria isola-
tion kit for cultured cells (Pierce Biotechnology, Rock-
ford, IL). Total cell lysate for intracellular ATP was
prepared by adding sterile water into wells. Mitochon-
drial and total ATP level were detected using ATP assay
kit (BMR Service) according to manufacturer’s instruc-
tion. Luminescence was measured by Veritas microplate
luminometer (Promega, Madison, WI) and ATP concen-
tration of each sample was normalized to the protein
concentration.
Measurement of glucose consumption and lactate
accumulation
Glucose assay kit and L-lactate assay kit (BMR service)
were used to measure concentration of glucose and
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cultures. Culture media were prepared at indicated days
and glucose and lactate levels were measured according
to manufacturer’s instructions. Absorbance was measure
at 492 nm and water (glucose) and DMSO (lactate) were
used to detect base lines.
Statistical analysis
Data are expressed as mean values ± standard deviation
(SD); p values were calculated with an unpaired two-
tailed Student’s t-test.
Results
BRAT1 expression is required for optimal proliferation
and viability
To detail the role of BRAT1 in cell proliferation, BRAT1
expression was stably knocked down in two different hu-
man cancer cells, U2OS (human osteosarcoma) cell line
and HeLa (human cervical carcinoma) cell line, using
BRAT1-targeted shRNA plasmids. Levels of BRAT1 were
determined by immunoblot analysis. Sh2, Sh16 clones
for U2OS cells and Sh3, Sh8 for HeLa cells showed
much lowered expression of BRAT1 among the stable
clones isolated and they were further studied for func-
tional analysis of the protein (Figure 1A).
First, we studied the effect of BRAT1 silencing on cell
growth by measuring cell number (Figure 1A) and the
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide, a yellow tetrazole) assay (Figure 1B). These ex-
periments show that BRAT1 knockdown in both U2OS
and HeLa cell lines results in extensive growth retardation.
Next, we tested cell cycle profile by DNA staining with
propidium iodide (PI), followed by flow cytometry analysis.
We found that BRAT1 knockdown U2OS cells showed
lower S-phase population (15.6 ± 2.7% in U2OS Sh2 and
16.2 ± 2.3% in U2OS Sh16) than control cells (30.2 ± 0.3%)
(Figure 1C). When treated with neocarzinostatin (NCS,
radio-mimetic chemical, 1 μg/ml), accumulation in G2/M-
phases was observed in control U2OS cells (59.3 ± 5.9%),
however this NCS-induced G2/M-arrest was abrogated in
U2OS Sh2 and Sh16 cells (33.27 ± 0.5 and 42.9 ± 2.2% re-
spectively), indicating that BRAT1 is involved in G2/M
checkpoint under conditions of DNA damage as shown in
our previous report [1]. Interestingly, U2OS Sh2 and Sh16
cells showed G1 arrest (10.3 ± 2.8 and 6.1 ± 1.0%, respect-
ively) to the similar degree with that of control U2OS cells
(7.8 ± 1.6%), when treated with hydroxyurea (Hu, 5 μM),
suggesting that BRAT1 is not essential for HU-induced
G1 checkpoint.
We next studied whether decrease in BRAT1 expres-
sion causes apoptosis. HeLa Sh3 cells were maintained
without changing media and apoptosis was determined
by Annexin V staining, followed by FACS analysis. We
found that HeLa Sh3 cells showed increase in apoptosis(Annexin AHigh/PILow) and necrosis (Annexin VLow/
PIHigh) when cell culture is maintained for 3 days (D3)
to 6 days (D6) compared to control cells (Figure 1D).
These results suggest that BRAT1 is required to main-
tain cell viability.
Loss of BRAT1 causes reduced cell migration and
tumorigenesis
Increased cell migration and tumor formation are key
characteristics of cancer cells. To further characterize
the BRAT1-knockdown cells, we performed wound heal-
ing and migration assay. Both control (NC) and HeLa
Sh3 and Sh8 cells were pretreated with mitomycin C be-
fore making injury lines to exclude the effect by prolifer-
ation. As shown in Figure 2A, wound healing activity of
BRAT1 knockdown cells was severely impaired. Roles of
BRAT1 in cell migration were studied with a migration
chamber (Figure 2B). Control and BRAT1 knockdown
MDA-MA-231 (231), human breast cancer cells, were
used for this assay, since MDA-MA-231 cells have been
frequently used for cell migration and penetration assay
using matrigel [19,20]. 231 cells were stably transfected
with nonspecific shRNA or 4 different BRAT1shRNA,
and then antibiotic-resistant clones were selected after 2
weeks as described. Knockdown of BRAT1 protein in
these stable cells was confirmed by immunoblot (insert
of Figure 2B). We found that 231 Sh2 and 231 Sh20 cells
showed significantly decreased mobility, compared with
control cells, which was determined by staining cells that
infiltrated the membrane. Quantified analysis showed
that migration of BRAT1 knockdown cells was more
than 3 fold lower than that of control cells.
Next, we examined the tumorigenicity of BRAT1 knock-
down cells in vivo by xenograft assay using HeLa Sh3 and
Sh8 cells. Control, HeLa Sh3 and HeLa Sh8 cells were
transplanted into nude mice (2 × 106 cell/mouse), and size
of the tumors was measured on day 5, 11, 13, 18, 19, 20,
21, 23, and 27. As shown in Figure 2C, tumor size of
BRAT1 knockdown cells was almost half of control HeLa
cells throughout the time course, indicating that BRAT1
regulates tumor cell growth. Together, these results indi-
cate that BRAT1 is involved in tumor cell growth, tumori-
genesis and cell motility.
The rate of glycolysis and dependency on glucose are
increased in BRAT1 knockdown cells
Increased glycolysis is one of the most prominent meta-
bolic alterations in cancer cells [13] and this metabolic
alteration increases aerobic glycolysis and dependency
on the cytoplasmic glycolytic pathway for ATP gener-
ation, instead of mitochondrial TCA cycle [16]. We ob-
served rapid changes of acidity of cell culture media of
BRAT1 knockdown cells compared to control cells (see
Additional file 1: Figure S1). Acidic pH in culture media
A B
C D
Figure 1 BRAT1 expression is required for optimal proliferation and viability. (A) NC (nonspecific shRNA) and Sh (selected BRAT1
knockdown cells) were selected and cloned from U2OS and HeLa parental cells after transfection with 4 different shRNA against BRAT1 mRNA.
The expression of BRAT1 was confirmed by immunoblot (inserts). Actin protein was used as internal control. The number of live cells (trypan blue
negative) was directly counted at indicated days. (B) 4 different BRAT1 knockdown HeLa cells (sh3, sh8, sh15, and sh17) were cultured for 3 days
(upper panel) and indicated days (bottom panel), then cell proliferation was measured using the MTT assay. (C) Both control and knockdown
U2OS cells were treated with NCS (1 μg/ml) or hydroxyurea (HU, 5 μM), then cultured for 24 h. Cells were fixed and stained with propidium
iodide (PI). DNA profile was analyzed by a flow cytometry. (D) Both control and BRAT1 knockdown cells were cultured for indicated times
without changing media, and then subjected to apoptosis analysis using AnnexinV/PI double stain. Apoptosis and necrosis were expressed by
percentage from total cells in dot plot graphs. Data are mean of three independent experiments. **Student’s t-test: p < 0.01.
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knockdown cells. To examine whether BRAT1 knock-
down results in the change of glucose metabolism, we
studied the rate of glucose consumption and lactate for-
mation in both control and BRAT1 knockdown cells
(Figure 3A). Increase in glucose consumption wasmeasured daily by concentration of glucose in culture
media. Compared to control cells, glucose concentra-
tion in culture media of HeLa Sh3 and Sh8 cells was
lower than that of control cells, indicating that knock-
down of BRAT1 results in higher glucose consumption.
Increase in glucose metabolism was confirmed by
A B
C
Figure 2 Loss of BRAT1 induces morphological changes and in vivo tumor growth. (A) The injury lines were made on confluent
monolayers of control (NC) and BRAT1 knockdown (sh3 and sh8) HeLa cells. Wound healing potential was analyzed under a light microscope
(×40) at indicated time points. (B) Both control (NC) and BRAT1 knockdown (sh2 and sh20) MDA-MA-231 cells were seeded onto migration
chamber and infiltrated cells were stained with 0.1% crystal violet, counted and then quantified (bottom). Percentage of migration was expressed
as ratio of migrating cells numbers of knockdown cells to control cells. The expression of BRAT1 was confirmed by immunoblot (inserts) Actin
protein was used as internal control. (C) Control and BRAT1 knockdown HeLa cells were injected into female nude mice as described in M&M.
Tumor size was measured at indicated days and then sacrificed at day 27. Tumors were isolated from individual mouse and photographs were
taken. Data were representative of three independent experiments.
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that HeLa Sh3 and Sh8 cells produce more lactate than
control cells (Figure 3A, right).
These results suggest that BRAT1 knockdown cells re-
quire more glucose for their growth. We further analyzed
glucose metabolism in BRAT1 knockdown cells by main-
taining cells with or without glucose in cell culture media,
and their apoptosis was measured on day 3 and day 5
(Figure 3B). Apoptosis was quantified by mean fluores-
cence intensity (MFI). On day 3, control HeLa cells
showed slight increase in apoptosis in glucose (−) media,
but HeLa Sh3 was more sensitive to glucose deprivation.
Increased sensitivity to glucose deprivation was more ob-
vious on day 5, when, compared to control HeLa cells,
HeLa Sh-3 cells showed much higher apoptosis.
2DG (2-deoxy-D-glucose) is a chemical analogous to
glucose, which inhibits glucose metabolism by causingglucose starvation [21-23]. Increased sensitivity of BRAT1
knockdown cells to glucose deprivation was further
studied to maintain those cells in the presence of 2DG
(5 mM). Early to late apoptosis was determined by
Annexin V staining using flow cytometry. As shown in
Figure 3C, 2DG treatment induced apoptosis of control
HeLa cells. Apoptosis of HeLa Sh-3 cells was constitu-
tively high, and it was further increased when cells were
treated with 2DG. These results support a notion that
BRAT1 knockdown cells are more sensitive to glucose
deprivation.
Loss of BRAT1 induces mitochondrial malfunctions
Several groups have suggested that DNA damage re-
sponse protein ATM is required for mitochondrial func-
tion, which ATM plays direct roles in modulating




Figure 3 The rate of glycolysis and dependency on glucose are increased in BRAT1 knockdown cells. (A) Culture media were harvested
from control or BRAT1 knockdown cell cultures at indicated day and then glucose consumption (left) and lactate accumulation (right) were
analyzed. (B) Control and BRAT1 knockdown cells were cultured with (glucose +) or without glucose (glucose -). Cells were harvested at indicated
day and stained with PI without fixation. PI positive cells were detected as apoptotic/necrotic cells. Data were expressed as mean fluorescence
intensity (ΔMFI = MFI of PI stained cells – MFI of unstained cells). (C) Cells were treated with or without 2DG (5 mM) for 24 h and then cellular
apoptosis was detected with AnnexinV/PI double staining by flow cytometry. Flow cytometry data were representatives of two different
experiments. (D) Culture media were daily changed and the number of living cells was counted after trypton blue staining.
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ROS [24,25]. As we reported previously, BRAT1 is es-
sential for the activation of ATM and DNA-PKcs [1,3,4].
Thus, we investigated whether BRAT1 is required for
mitochondrial functions.
First, we found that distribution of mitochondria in
HeLa knockdown clone is different from that of control
cells when cells are stained with dye that localizes mito-
chondria. In control cells, mitochondria localization is dis-
persed in the cytoplasm, but it is more condensed in
BRAT1 knockdown cells (see Additional file 2: Figure S2).
Because proper mitochondrial distribution is essential formitochondrial functions, such as ATP delivery and cal-
cium regulation [26], this change in mitochondrial distri-
bution suggests that BRAT1 is involved in mitochondria
homeostasis. Supporting this model, we found that
BRAT1 localizes in both nuclear and cytoplasm [1]. Thus,
cytoplasmic BRAT1 might be involved in this mitochon-
dria regulation. Based on preliminary data, we tested the
production of superoxide by mitochondria with fluores-
cence microscopy using the MitoSOX reagent. It perme-
ates live cells where it selectively targets mitochondria,
and is rapidly oxidized by superoxide but not by other re-
active oxygen species (ROS) and reactive nitrogen species
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drial superoxide is significantly increased in HeLa Sh3
cells, compared to the control cells. Intensity of fluores-
cence was quantified by MFI.
Next, we monitored the generation processes of reactive




Figure 4 BRAT1 is required for mitochondrial functions. Mitochondrial
(sh3) HeLa cells were detected by mitosox (red), CM-H2DCFDA (green), and
(right) were expressed as ΔMFI. (C) Control and BRAT1 knockdown HeLa ce
for flow cytometry. The percentage of JC-1 monomer positive cells was exp
BRAT1 knockdown (sh15 and sh17) HeLa cells and then subjected to array
492 nm using a microplate reader. (E) Mitochondria were isolated from co
then ATP concentration were measured as μM/μg proteins (left). Total cell
Data were representative of three independent experiments. **Student’s t-2’,7’-dichlorfluorescein-diacetate (DCFH-DA), which has
been broadly used as a compound to detect and quantify
intracellular produced ROS. Quantified fluorescent signal
analysis determined by MFI indicated that HeLa Sh3 cells
contain much higher levels of ROS compared to the par-
ental HeLa cells (Figure 4B).D
(A) and cellular (B) ROS levels in control (NC) and BRAT1 knockdown
DAPI using fluorescent microscopy. Quantitative flow cytometry data
lls were stained with JC-1 dye at 2.5 μg/ml for 10 min and harvested
ressed in gates. (D) Total lysate was isolated from control (NC) and
for PDH activity. The activity was expressed as O.D. per mg protein at
ntrol (NC) and BRAT1 knockdown (sh15 and sh17) HeLa cells, lysed and
extracts from same cells were also analyzed for total cellular ATP (right).
test: p < 0.01.
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1,1′,3,3′-tetraethylbenzimidazolocarbo-cyanine iodide) dye
is widely used to monitor mitochondrial health, and can
be used as an indicator of mitochondrial membrane poten-
tial in a variety of cell types. The dissipation of the mito-
chondrial electrochemical potential gradient is known as
an early event in apoptosis. In normal cells, due to the
electrochemical potential gradient, the JC-1 concentrates
in the mitochondrial matrix. Any event that dissipates the
mitochondrial membrane potential prevents the accumu-
lation of the JC-1 dye in the mitochondria and thus, the
dye is dispersed throughout the entire cell leading to a
shift to green fluorescence (JC-1 monomers). When we
tested JC-1 signal of control, Sh3 and Sh8 HeLa cells, we
observed increase in JC-1 monomeric signals in both HeLa
Sh3 and Sh8 cells, illustrating mitochondrial dysfunction
in HeLa Sh3 and Sh8 cells (Figure 4C).
Taken together, these results suggest that BRAT1 de-
pletion results in mitochondrial malfunction, leading to
increased metabolism of glucose consumption. It is as-
sumed that these cells are more sensitive to glucose
deprivation.
Pyruvate dehydrogenase (PDH) transforms pyruvate into
acetyl-CoA, contributing to linking the glycolysis meta-
bolic pathway to the tricarboxylic acid (TCA) cycle [27].
ATP production from mitochondria is one of criteria to
evaluate mitochondrial function [28]. In this assay, en-
dogenous PDH reduces tetrazolium salt, INT (2-p-iodo-
phenyl-3-nitrophenyl-5-phenyl tetrazolium chloride) to
INT-formazan in a NADH-coupled reaction. The intensity
of the red color formed is increased in the presence of in-
creased PDH activity. As shown in Figure 4D, PDH activity
was reduced in BRAT1 knockdown cells. Next, we tested
if BRAT1 is involved in mitochondrial or cytoplasmic ATP
production. In this assay, enzyme luciferase catalyzes the
oxidation of luciferin, in ATP-dependent manner, which
can be measured by a luminometer. As shown in Figure 4E,
the level of mitochondrial ATP was significantly lower in
BRAT1 knockdown cells compared with control cells, but
the total levels of cellular ATP were not significantly dif-
ferent. These results indicate that ATP production from
mitochondria is decreased in BRAT1 knockdown cells,
suggesting that BRAT1 cells shift their energy source to-
ward glycolysis to generate their ATP supply. Taken to-
gether, present data demonstrate that BRAT1 plays a
critical role in regulating mitochondrial functions.
BRAT1 is required for constitutive Akt activation, and Akt
activation by SC79 partially restores BRAT1 knockdown cells
It has been well documented that PI3K/Akt and extra-
cellular signal-regulated kinase (Erk) signaling cascades
regulate a wide variety of cellular processes, such as cell
proliferation, differentiation, survival, cell transformation
and metastasis of tumor cells [29,30]. Further, Aktactivation stimulates glucose consumption in trans-
formed cells, and constitutive active Akt-expressing cells
were more susceptible to glucose deprivation than Akt-
deficient cells [31]. Also recent works suggested that
mitochondrial stress leads to increased expression, acti-
vation, and nuclear localization of Akt [32]. Together,
these works suggested that glucose metabolism inhibits
mitochondrial oxidation and suppresses apoptosis and
increase proliferation in cancer cells by Akt-mediated
signal. However, mitochondrial failure without increase
in glucose metabolism suppresses cell growth and in-
crease apoptotic phenotypes of cancer cells [33,34].
Because our data showed that mitochondria function is
impaired in BRAT1 knockdown cells, we studied whether
growth promoting pathways are activated in those cells.
The expression of Akt, Erk and their phosphorylation sta-
tus were assessed by western blotting. As shown in
Figure 5A, phosphorylation of both Akt and Erk decreased
in BRAT1 knockdown cells. Serum-induced activation of
these kinases is significantly reduced in knockdown cells.
Given the low migration and tumorigenesis of BRAT1
knockdown cells, these results suggest that phosphory-
lated Akt is indicative of reduced cell proliferation. We
continue to study the mechanism of lowered Akt phos-
phorylation of BRAT1 knockdown cells, even though
these cells consume more glucose than the control cells.
Recently, Luo’s laboratory developed a novel Akt activa-
tor (SC79) which augments neuronal survival in mouse
model for ischemic stroke [35]. SC79 directly enhanced
Akt phosphorylation of all Akt isoforms and increases Akt
activity in multiple cell types, including HeLa, HL60,
HEK293, NB4 and HsSulton cells. When HeLa Sh3 cells
were treated with SC79, Akt’s phosphorylation at Ser473
and Thr308 were induced, although it was slightly weaker
than that of control cells (Figure 5B). We explored the ef-
fect of SC79 on cell proliferation of BRAT1 knockdown
cells using MTT assay. As shown in Figure 5C, SC79 treat-
ment restored proliferation of BRAT1 knockdown cells to
the similar degree of control cells. We also found that
SC79 reduces the production of superoxide in mitochon-
dria that was detected by MitoSox positive cells (Figure 5D).
These data clearly indicate that the loss of BRAT1 inhibits
growth signaling cascades mediated by Akt pathways.
Discussion
It has been implicated that BRAT1 might be a regulator
for ATM and DNA-PK activation in response to DNA
damage induced by ionizing radiation (IR) or chemicals
[4]. Interestingly, silencing of BRAT1 increased constitu-
tive apoptosis and reduced cell growth. In this study, we
determined a role for BRAT1 in proliferation and mito-
chondrial functions. After confirming suppressed BRAT1
expression, we found reduced BRAT1 expression in mul-




Figure 5 Loss of BRAT1 leads to inhibition of Akt activity and Akt activation by SC79 partially restores BRAT1 knockdown cells.
(A) Control (NC) and BRAT1 knockdown (sh3) HeLa cells were cultured in DMEM media with 10% serum (M). To examine serum-induced
activation, cells were cultured in DMEM media without serum (SF and SFS) for 24 h and then continuously cultured with 10% serum (SFS) or
without serum (SF) for 1 h. Protein extracts were blotted using indicated antibodies for phospho- or whole proteins. Actin protein was used as
internal control. (B) Cells were cultured with (media) or starved for 24 h and then serum was added into these media. SC79 (5 μg/ml) were
treated at 2, 10 μg/ml for 30 min and then total extracts were analyzed for phosphorylation and expression of indicated protein by immunoblotting.
(C) Cells were cultured with or without SC79 for indicated time and then cell proliferation was measured using MTT assay. More SC79 was added at D2
and D4 (down arrow). (D) Cells were cultured with or without SC79 (5 μg/ml) for 24 h and stained with mitosox for 10 min. Flow cytometry was
conducted to detect mitosox positive cells (gated) from control and BRAT1 knockdown cells. Quantified flow cytometry data (left) were representative
of two independent experiments (right). *Student’s t-test: p < 0.05.
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and 2). This data suggests that BRAT1 has play a role in
tumorigenesis, but further studies will be needed to
identify BRAT1 role for whole tumor progress, including
metastasis of specific tumor models.
It was interesting that BRAT1 knockdown cells used in-
efficient glucose, leading to fast reduction in pH. We first
found acidic extracellular pH through phenol red color
(Figure S1). Although BRAT1 knockdown decreased cell
proliferation, higher glycolysis and increased lactate accu-
mulation were observed in BRAT1 knockdown culture
media (Figure 3A), suggesting that glucose metabolism
was modulated in correlated with reduced expression of
BRAT1. To support this notion, we showed the glucose
deprivation and blocking glycolysis by 2DG induce more
severe apoptosis in BRAT1 knockdown cells than in con-
trol hela cell (Figure 3B and C). However, our data sug-
gests that increased dependency on glucose is not direct
reason of growth retardation and constitutive apoptosis as
shown in BRAT1 knockdown cells (Figure 3D).
Several possibilities could be suggested why glucose con-
sumption might be increased in BRAT1 knockdown cells.
These mechanisms may include mitochondrial malfunc-
tion and oncogenic signaling, such Ras and Akt [31,36].
Mitochondrial oxidative phosphorylation and cytoplasmic
glycolysis are two main metabolic pathways by which ATP
is generated for energy supply [37]. Mitochondrial mal-
function has been implicated to be responsible for in-
creased glycolysis [16]. Impaired mitochondrial function
also causes pyruvate accumulation in cancer cells [38].
Therefore, we reasoned that high glucose consumption
might be due to mitochondrial malfunction. Data in
Figure 4 shows that 4 different analyses revealed aber-
rant mitochondrial functions and metabolic pathways.
In other words, elevated level of ROS, lower mitochon-
drial membrane potential, impaired PDH activity, and
decreased production of ATP from mitochondria in
BRAT1 knockdown cells clearly describe that BRAT1
has play a critical role in mitochondrial functions.
It was reported that mitochondrial respiration defects
lead to activation of Akt survival pathway through a
mechanism mediated by NADH, describing how meta-
bolic alteration in cancer cells gain a survival advantage
[15]. Also recent work suggested that mitochondrial stress
leads to increased expression, activation, and nuclear
localization of Akt [36]. Because our data showed a series
of mitochondrial-originated stresses, we expected that Akt
pathway might be constitutively activated in BRAT1
knockdown cells. However, both basal and serum-induced
activation of Akt were reduced in BRAT1 knockdown cells
(Figure 5A and 5B), suggesting that knockdown-induced
cellular and mitochondrial stress is not able to activate
Akt. Further, Erk phosphorylation was also decreased in
these cells. Akt and Ekr-mediated signaling pathways arecritical steps for a wide variety of cellular processes, in-
cluding cell survival, growth, proliferation, metabolism
and migration [29,30]. Thus, we couldn’t detect any
stress-induced Akt or Erk activation in BRAT1 knock-
down cells, instead, results implicates that BRAT1is in-
volved in Akt/Erk-mediated growth regulation. SC79
can enhance Akt-PDK1 interaction, leading to enforced
phosphorylation at Thr308 and Ser473 of Akt [35].
Using SC79, we confirmed Akt activation can moder-
ately restore cell growth and ROS level (Figure 5C and
5D). Although SC79 treatment was able to induce Akt
phosphorylation in knockdown cells, the level of
phosphorylation was less than control, suggesting that the
upstream of Akt might be impaired by suppressed expres-
sion of BRAT1. It is interesting further study to investigate
whether BRAT1 is involved in PI3K/mTOR/Akt signaling
pathway, leading to optimal growth and keeping metabolic
homeostasis of mitochondria.
So far, BRAT1 has been the only DNA damage response
protein, which regulates reaction stability of ATM/DNA-
PK, leading to genomic stability after DNA damaging
stress. However, this protein seems to account for prolifer-
ation and cellular metabolism in correlated with mito-
chondrial functions. Genetic investigation of patients with
mutated BRAT1 suggests that BRAT1 plays a role on
neuronal development [5]. They found deletion mutant of
BRAT1 in patient, however it remains to be clear how this
mutation affect disease development.Conclusions
In the current studies, we demonstrate that loss of BRAT1
induces mitochondrial malfunctions, suppresses growth
signaling, and increase steady-state levels apoptosis. We
also show that growth retardation in BRAT1 knockdown
cells is due to mitochondrial malfunction that causes in-
creased ROS and decreased ATP production. It has been
illustrated that BRAT1 regulates activation of ATM and
DNA-PK under conditions of DNA damaging stress.
Present results indicate that BRAT1 is also involved in
cell proliferation and mitochondrial metabolism. Because
ATM-deficient cells showed mitochondrial dysfunction
[29], abnormal cellular differentiation/development [39],
and impaired Akt activation [40], our results further sup-
port the model that BRAT1 determines the phenotypes
caused by ATM deficiency.Additional files
Additional file 1: Figure S1. Remarkable PH changes in media from
BRAT1 knockdown cultures compared to that from control culture. PH of
media from control (NC) and BRAT1 knockdown (sh3 and sh8) HeLa cell
cultures were directly recorded by PH meter (Mettler-Toledo, LLC, OH) at
day 2 and day 5 after seeding (2× 105/6 cm culture dish).
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http://www.biomedcentral.com/1471-2407/14/548Additional file 2: Figure S2. Loss of BRAT1 induces morphological
changes. (A) Both control (NC) and knockdown (sh3) HeLa cells were
seeded onto 6 cm plates and cultured for 24 h. Cells were treated with
MitoTracker (MT) for 10 min before fixation, then morphological features
were analyzed. (B) Both control (NC) and BRAT1 knockdown (sh20)
MDA-MA-231 cells were examined with a bright field inverted
microscope (Nikon).
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